Organon Strikes $100m+ Global Deal For Henlius’ Denosumab And Pertuzumab

Gains Rights To Perjeta And Prolia/Xgeva Biosimilars As Well As Ipilimumab Option

Deal handshake with US and China flags
US-based Organon has struck a deal with China’s Henlius • Source: Shutterstock

More from Deals

More from Business